source · text/csv
source_8df84d1cd09147ec
sha256 2dfb8f33a0ae68ebb7a3bba102b43661712f359e5c44f5c80430431cab8f47d1
by researka:v2 · 2026-06-01 06:14:42.780133+04:00
study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "7ab156d6-8b98-4d64-9135-9b29624ec48e",
"researka_submission_id": "fc9da6e7-a490-4a9c-99da-921c81b22c8c",
"sidecar_name": "evidence_table.csv",
"sidecar_url": "https://api.researka.org/publications/7ab156d6-8b98-4d64-9135-9b29624ec48e/sidecars/evidence_table.csv"
}